Finland · Delayed Price · Currency is EUR Orion Oyj Company Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.
It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use.
The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies.
Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products.
It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa.
Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
| Country | Finland |
| Founded | 1917 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 4,029 |
| CEO | Liisa Hurme |
Contact Details
Address: Orionintie 1A Espo, 02200 Finland | |
| Phone | 358 10 4261 |
| Website | orionpharma.com |
Stock Details
| Ticker Symbol | ORNAV |
| Exchange | Nasdaq Helsinki |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FI0009014369 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Liisa Hurme Ph.D. | President, Chief Executive Officer and Chairman of Executive Management Board |
| Rene Lindell M.Sc., Ph.D. | Chief Financial Officer and Member of Group Executive Management Board |
| Satu Ahomäki M.Sc., M.Sc. (Econ.) | Executive Vice President of Generics and Consumer Health and Member of the Exe. Mgmt. Board |
| Prof. Outi Vaarala M.D., Ph.D. | Executive Vice President of Innovative Medicines and Research & Development and Member of the Exe. Mgmt. Board |
| Juhani Kankaanpaa M.Sc. | Executive Vice President of Global Operations and Member of Executive Management Board |
| Niclas Lindstedt EMBA, M.Sc. | Executive Vice President of Animal Health and Member of the Exe. Mgmt. Board |
| Hao Pan M.Sc. | Executive Vice President of the Branded Products and Member of the Exe. Mgmt. Board |
| Julia Irene Macharey | Executive Vice President of People and Culture & Member of Management Board |
| Mikko Kemppainen | General Counsel, Secretary to the Board and Member of Executive Management Board |
| Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations and Financial Communications Officer |